Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews · Airways

No studies found 0 · 0%GRADE not reported 1 · 33.3%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 2 · 66.7%

Serious adverse events · people with asthma

Reslizumab intravenous (IV) showed no clear difference in serious adverse events compared with placebo (high certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
Risk ratio 0.79 [0.56, 1.12]
4 studies · 1656 participants
High

Serious adverse events · people with asthma

Mepolizumab intravenous (IV) leads to lower serious adverse events compared with placebo (high certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
Risk ratio 0.59 [0.37, 0.94]
3 studies · 751 participants
High

Proportion of people with serious adverse events · acute exacerbations of chronic obstructive pulmonary disease

1 finding from 1 review

Magnesium sulfate for acute exacerbations of chronic obstructive pulmonary disease 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 77 participants
GRADE not reported